Glycemic Outcomes of Second-Line Diabetes Drug Choice in a Real-World Population

Glycemic Outcomes of Second-Line Diabetes Drug Choice in a Real-World Population

Hypoglycemia and acute metabolic complications (AMCs; ketoacidosis, hyperosmolarity, and coma) are glycemic outcomes that have high cost and high morbidity; these outcomes must be taken into consideration when choosing initial second-line therapy after metformin. We conducted a retrospective cohort...

Full description

Bibliographic Details
Main Authors: Amisha Wallia, MD, MS, Matthew J. O’Brien, MD, MSc, David T. Liss, PhD, Raymond H. Kang, MA, Andrew J. Cooper, MSc, Amy Gilmer, BA, Ronald T. Ackermann, MD, MPH
Format: Article
Language:English
Published: Elsevier 2021-06-01
Series:Mayo Clinic Proceedings: Innovations, Quality & Outcomes
Online Access:http://www.sciencedirect.com/science/article/pii/S254245482100045X

Internet

http://www.sciencedirect.com/science/article/pii/S254245482100045X

Similar Items